MRTX849 is primarily used in the treatment of cancers with specific genetic mutations. It is a targeted therapy designed to inhibit the activity of mutated KRAS proteins, particularly the KRAS G12C mutation, which is commonly found in certain types of lung, colorectal, and pancreatic cancers. By blocking this mutation, MRTX849 helps to slow down or stop the growth of cancer cells. It is often administered orally and is being studied in clinical trials to evaluate its effectiveness, either as a standalone treatment or in combination with other therapies. Its development represents a significant advancement in precision medicine for patients with KRAS-driven cancers.